Search filters
Filters
Clear All

Phase

  • 54
  • 61
  • 2
  • 53
  • 1
  • 51
  • 11
  • 670
  • 926
  • 606
  • 5
  • 39
  • 886

Found 930 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

GYROS

99 years and younger
All genders
Gyrate atrophy (GA) is a rare inherited chorioretinal degeneration that is associated with hyperornithinemia, an inborn error of metabolism caused by autosomal recessive mutations in the ornithine aminotransferase (OAT) gene. The current standard care treatment of GA is an arginine restricted diet. To facilitate a future interventional gene therapy clinical …
Learn More

BACKBEAT

99 years and younger
All genders
This is a prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel AV interval modulation (AVIM) algorithm downloaded into a previously implanted dual-chamber Medtronic pacemaker. Patients within 90 days of de novo implant of an Astra/Azure pacemaker also having uncontrolled hypertension may be approached for …
Learn More

DRCR AO

99 years and younger
All genders
Patients with nAMD most commonly receive an anti-VEGF injection into the eye. A "Treat and Extend" method is used to determine how often injections are needed. OCT scans of the eye are used to determine when to give treatment. This study seeks to see how using a Home OCT device …
Learn More

UPCC 29421: Administration of HIV-specific T cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue -Auto-RESIST

99 years and younger
All genders
Were doing this study to see if a type of cells called HST-NEETs can help the body fight HIV. HST-NEETs are cells made from immune cells that have been treated and grown in a lab. This is a phase 2 study.
Learn More

An extension study to evaluate the long-term efficacy and safety of minzasolmin (UCB0599) in study participants with Parkinsons disease

99 years and younger
All genders
Subjects currently enrolled in the PD0053 can be enrolled in this study. Subjects will take UCB0599 capsules twice a day at either 180 mg or 360 mg approximately 12 hours apart. The start of the study will overlap with the end of the parent study and run for 30 months …
Learn More

A011801 The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with

99 years and younger
All genders
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer.
Learn More

ECOG EA6174 A Phase III Randomized Trial Comparing Adjuvant MK- 3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

99 years and younger
All genders
This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere …
Learn More

UPCC 11220: BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

99 years and younger
All genders
The study will enrollsubjects who have undergone surgery for stage II or III colorectal cancer and who have residual FFPE tissue available will provide FFPE and whole blood samples. Subjects will receive SIGNATERA test results and may be recommended for adjuvant chemotherapy or observation by their treating clinician.The study also …
Learn More

R3918-MG-2018

99 years and younger
All genders
This protocol is to see the affects of different combination therapy of Pozelimab and Cemdisiran in patient's with Symptomatic generalized myasthenia gravis. The study is split into 5 different parts: Screening. randomization and double blind study treatment period, double blind extension study treatment period, open-label study treatment period, and follow …
Learn More

UPCC 53923: A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types

99 years and younger
All genders
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies. We would like to rely on Advarra as the IRB of record for this study.
Learn More
691 - 700 of 930